| pubmed-article:11642610 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11642610 | lifeskim:mentions | umls-concept:C0376659 | lld:lifeskim |
| pubmed-article:11642610 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:11642610 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:11642610 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:11642610 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:11642610 | lifeskim:mentions | umls-concept:C2347946 | lld:lifeskim |
| pubmed-article:11642610 | pubmed:issue | 1-3 | lld:pubmed |
| pubmed-article:11642610 | pubmed:dateCreated | 2001-10-19 | lld:pubmed |
| pubmed-article:11642610 | pubmed:abstractText | Successful application of active immunotherapy to the treatment of cancer will require stimulation of potent antigen-specific T-cell responses. It is not known how numerous or how potent these T cells must be in order to abrogate tumors, but the levels of immunity needed to control chronic viral infections may provide estimates for comparison. Evaluation of the efficacy of a vaccine strategy in attaining these levels of immunity will depend on the use of assays that create a picture of T-cell number and function that correlates with clinical outcomes. We discuss the currently available in vivo and in vitro T-cell assays and their relevance for detecting therapeutic levels of T-cell activity. We also propose a strategy for efficiently evaluating the immunologic efficacy of cancer vaccines so that the most promising candidates can be brought more rapidly into definitive clinical trials. | lld:pubmed |
| pubmed-article:11642610 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11642610 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11642610 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11642610 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11642610 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11642610 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11642610 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11642610 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11642610 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11642610 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11642610 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11642610 | pubmed:issn | 1040-8401 | lld:pubmed |
| pubmed-article:11642610 | pubmed:author | pubmed-author:ChiuL ELE | lld:pubmed |
| pubmed-article:11642610 | pubmed:author | pubmed-author:MorseM AMA | lld:pubmed |
| pubmed-article:11642610 | pubmed:author | pubmed-author:LyerlyH KHK | lld:pubmed |
| pubmed-article:11642610 | pubmed:author | pubmed-author:MoscaP JPJ | lld:pubmed |
| pubmed-article:11642610 | pubmed:author | pubmed-author:HobeikaA CAC | lld:pubmed |
| pubmed-article:11642610 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11642610 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:11642610 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11642610 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11642610 | pubmed:pagination | 287-97 | lld:pubmed |
| pubmed-article:11642610 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:11642610 | pubmed:meshHeading | pubmed-meshheading:11642610... | lld:pubmed |
| pubmed-article:11642610 | pubmed:meshHeading | pubmed-meshheading:11642610... | lld:pubmed |
| pubmed-article:11642610 | pubmed:meshHeading | pubmed-meshheading:11642610... | lld:pubmed |
| pubmed-article:11642610 | pubmed:meshHeading | pubmed-meshheading:11642610... | lld:pubmed |
| pubmed-article:11642610 | pubmed:meshHeading | pubmed-meshheading:11642610... | lld:pubmed |
| pubmed-article:11642610 | pubmed:meshHeading | pubmed-meshheading:11642610... | lld:pubmed |
| pubmed-article:11642610 | pubmed:meshHeading | pubmed-meshheading:11642610... | lld:pubmed |
| pubmed-article:11642610 | pubmed:meshHeading | pubmed-meshheading:11642610... | lld:pubmed |
| pubmed-article:11642610 | pubmed:meshHeading | pubmed-meshheading:11642610... | lld:pubmed |
| pubmed-article:11642610 | pubmed:meshHeading | pubmed-meshheading:11642610... | lld:pubmed |
| pubmed-article:11642610 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11642610 | pubmed:articleTitle | Quantitating therapeutically relevant T-cell responses to cancer vaccines. | lld:pubmed |
| pubmed-article:11642610 | pubmed:affiliation | Department of Surgery, Duke University Medical Center, Durham, NC, USA. | lld:pubmed |
| pubmed-article:11642610 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11642610 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:11642610 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:11642610 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11642610 | lld:pubmed |
